中药注射剂治疗冠心病的系统评价再评价

该研究旨在对中药注射液治疗冠心病的系统评价进行再评价。计算机检索中英文数据库,查找中药注射液治疗冠心病的系统评价,制定纳排标准和数据提取表,采用AMSTAR量表、PRIMSA声明对纳入文献进行方法学质量评价和报告质量评价。最终纳入69个系统评价,涉及24种中药注射剂,其治疗冠心病有一定疗效,主要结局指标有改善心绞痛症状和心电图改善等,所纳入系统评价均未报告结局指标随访时间,6个系统评价报道了中药注射剂治疗冠心病的中医证型,44个系统评价中有1 335个研究提及4 137例发生了不良反应。对纳入研究进行质量评价的评分不高,大部分系统评价存在异质性资料和森林图标识处理不合理问题。治疗冠心病的中药注射剂种类广泛且具有一定疗效,但由于系统评价质量偏低和系统评价再评价制作过程影响,该研究存在一定局限性,因此,所获得的支持证据强度有待进一步提升,以期为临床医生提供更高级的临床证据。

Reevaluation for systematic reviews for traditional Chinese medicine injections for coronary disease

To reevaluate the systematic reviews for traditional Chinese medicine(TCM) injections for treating coronary disease, data in four Chinese databases and PubMed, Embase, Cochrane Library, Wed of Science OVID from inception until May 2016 were searched. We extracted data according to the AMSTAR and PRISMA checklists to evaluate the methodological quality and reporting characteristics of included literatures. A total of 69 systematic reviews were included, involving 24 TCM injections, which showed certain efficacy in treating coronary disease, and whose main outcome indexes included alleviation of symptoms of angina pectoris and electrocardiogram. In all of the systematic reviews, the duration of follow-up were not reported. Six systematic reviews reported TCM typing. In the 44 system reviews, 1 335 reports mentioned 4 137 adverse events. According to the results of AMSTAR and PRISMA checklists, the quality assessment scores about included studies were not high, and most of the systematic reviews suffered heterogeneity and irrational processing of forest plots. In conclusion, TCM injections in the treatment of coronary disease have a wide range and positive effects. However, affected by the low quality of systematic reviews and the production of reevaluation, the study had some limitations. Therefore, the systematic reviews shall be further improved, in order to provide more advanced clinical evidences to clinicians.